Comment on Boyko and Jensen. Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725–2728

Rivas-Crespo, M. Francisco

doi:10.2337/dc15-1172

Cited by 6 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…My colleagues and I appreciate Dr. RivasCrespo's interest in our work and his confirmation that our reformulation of HOMA to demonstrate that it is no different than QUICKI is mathematically correct (1). Rivas-Crespo does take issue with the value of the constant in the reformulation that we presented in 2007 (2).…”

mentioning

confidence: 85%

See 1 more Smart Citation

Response to Comment on Boyko and Jensen. Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725–2728

Boyko

2015

Diabetes Care

View full text Add to dashboard Cite

mentioning

confidence: 85%

“…Nevertheless, we do not understand why Rivas-Crespo describes these alternative formulations as "somewhat imprecise," given that he writes earlier in his article that "the mathematical facts appear to be right" (1). With regard to the presence of error, the only evidence we can find for it is the erroneous claim in his article that it exists.…”

mentioning

confidence: 86%

Response to Comment on Boyko and Jensen. Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725–2728

Boyko

2015

Diabetes Care

View full text Add to dashboard Cite

“…Serum was separated and insulin levels were assayed using ELISA kits purchased from chemux BioScience, Inc. (Catalogue Number: 10801, Germany) according to manufacturer's instruction, with a sensitivity of 2µIU/mL. Homeostasis model assessment of insulin sensitivity (HOMA-IR) was estimated using equation HOMA-IR = fasting glucose level (mg/dl) × fasting insulin level (µU/mL)/405 [14]. Serum DICER-1 levels were assayed using human DICER1 ELISA kit, purchased from SunRed Hotechnology Company (Catalogue number: 201-12-9072, Shanghai).…”

Section: Biochemical Investigationsmentioning

confidence: 99%

Regulation of MicroRNA 103 and 107 in Obese T2DM Patients Maintained on Metformin

El-Ashmawy

Gawaly

Batanony

et al. 2021

Preprint

View full text Add to dashboard Cite

Metformin increases insulin sensitivity in obese type 2 diabetic patients (T2DM) by different mechanisms. The current study was conducted to estimate the levels of miRNA-103 and 107 in obese non diabetic subjects as well as obese T2DM patients maintained on metformin, and to correlate between the levels of miR 103 and 107 and the development of insulin resistance. Ninety subjects were equally recruited into three groups; obese non diabetic control (OC), obese newly diagnosed diabetic (ONDD) and obese type 2 diabetic treated with metformin (MetD). Serum levels of blood glucose, insulin, lipid profile, glycosylated hemoglobin (HbA1c), miR103&107 expression and DICER-1 were analyzed. Serum levels of HbA1c, FBG, HOMA-IR, T.ch, TG, LDL-C and VLDL-C were increased in ONDD (p˂0.0001) compared to OC and MetD. Significant increase of HDL-C (p = 0.022) was observed in MetD compared to OC and ONDD. Serum insulin was increased (p = 0.004) and miR 103 & 107 gene expression (p < 0.0001) in ONDD and significant down-regulation in MetD compared to OC group. DlCER-1 levels were decreased (p < 0.0001) in ONDD group and increased in MetD group compared to OC group. Both miR 103 and 107 were positively correlated with insulin and HOMA-IR, but negatively correlated with DICER-1. Depending on the estimated cutoff-values of area under receiver curve (AUC), miR 103 and 107 were excellent diagnostic biomarkers for insulin resistance. Our findings indicated the clinical utility of miR103 and miR 107 in diagnosis and treatment of insulin resistance. Moreover, metformin can affect miR 103 and miR 107 through modulation of DICER-1 level.

show abstract

“…The frequency of type 2 diabetes was assessed based on participants' self-report of taking medication for diabetes and/or having a fasting plasma glucose (FPG) level ≥126 mg/dl and/or HbA1c values of ≥6.5% at time of data collection. Insulin resistance was calculated using the Homeostatic Model Assessment for Insulin Resistance: HOMA-IR (fasting glucose [mg/dl]/fasting insulin [mU/L]/405; [Rivas-Crespo, 2015]). Hypertension was defined as elevated blood pressure (systolic blood pressure [BP] ≥ 140 mm Hg and/or diastolic BP ≥90 mm Hg) or reported hypertension medication use.…”

Section: Cardiometabolic Disease Definitionsmentioning

confidence: 99%

C‐reactive protein in adult Samoans: Population variation and physiological correlates

Rivara

Corley

Choy

et al. 2021

American J Hum Biol

View full text Add to dashboard Cite

Objectives: C-reactive protein (CRP) has been associated with adiposity and cardiometabolic disease risk in many populations but remains remarkably understudied in Pacific Islander populations. Here, we provide the first examination of correlates of CRP in adult Samoans (n = 108, ages 35-55 years) to test the hypotheses that CRP exhibits sex-dependent associations with measures of BMI, adiposity, and cardiometabolic disease risks.Methods: We analyzed associations between measures of adiposity (total fat mass, visceral fat mass, percent total body fat), body mass index (BMI), cardiometabolic risks, behaviors, demographics, and CRP. Unadjusted analyses of CRP were undertaken using Pearson's pairwise, and Spearman's rank correlations; one-way analysis of variance and Kruskal-Wallis tests assessed variables by CRP quartiles. Adjusted analyses of CRP correlates were examined using generalized linear regression.Results: Serum CRP ranged from 0.08 to 13.3 mg/L (median 1.4 mg/L) and varied significantly by sex t (108) = À2.47, p = .015. CRP was weakly to moderately associated with measures of adiposity and BMI (r and ρ ranged between 0.25 and 0.50, p < .05) and some cardiometabolic markers (including HbA1c,

show abstract

Comment on Boyko and Jensen. Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725–2728

Cited by 6 publications

References 5 publications

Response to Comment on Boyko and Jensen. Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725–2728

Response to Comment on Boyko and Jensen. Do We Know What Homeostatis Model Assessment Measures? If Not, Does It Matter? Diabetes Care 2007;30:2725–2728

Regulation of MicroRNA 103 and 107 in Obese T2DM Patients Maintained on Metformin

C‐reactive protein in adult Samoans: Population variation and physiological correlates

Contact Info

Product

Resources

About